Corcept Therapeutics (CORT) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Corcept Therapeutics (CORT) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 32.4% versus a gain of 11.8%. Over five years, CORT leads with a +496.8% price change compared with +466.0% for MDGL. Corcept Therapeutics is the larger company by market cap ($12.93 billion vs $11.27 billion), about 1.1 times the size, while Madrigal Pharmaceuticals is growing revenue faster (+432.1% vs +12.8%).
On valuation, Corcept Therapeutics trades at a lower forward P/E (27.2x vs 50.7x for Madrigal Pharmaceuticals). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -30.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CORT | MDGL |
|---|---|---|
| Share price | $119.60 | $487.72 |
| Market cap | $12.93B | $11.27B |
| 1-day change | +0.03% | -1.76% |
| YTD return | +243.68% | -16.25% |
| 1-year return | +32.42% | +11.79% |
| 5-year return | +496.81% | +466.00% |
| P/E ratio (TTM) | 265.78 | — |
| Forward P/E | 27.17 | 50.67 |
| EPS (TTM) | $0.45 | $-12.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $761.41M | $958.40M |
| Revenue growth (YoY) | +12.79% | +432.05% |
| Net income (latest FY) | $99.65M | $-288.28M |
| Gross margin | 98.30% | — |
| Operating margin | 5.88% | -31.31% |
| Net margin | 13.09% | -30.08% |
| 52-week high | $126.38 | $615.00 |
| 52-week low | $28.66 | $393.61 |
| Distance from 52-week high | -5.36% | -20.70% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +17.89% | +39.86% |
| Average volume | 1.31M | 292.63K |
| Shares outstanding | 108.10M | 23.10M |
| Employees | 730 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CORT has outperformed MDGL by 20.6 percentage points over the past year.
- Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +12.79%).
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
CORT vs MDGL FAQ
Which is bigger, Corcept Therapeutics or Madrigal Pharmaceuticals?
Corcept Therapeutics (CORT) is larger, with a market capitalization of $12.93B compared with $11.27B for Madrigal Pharmaceuticals (MDGL).
Which stock has performed better over the past year, CORT or MDGL?
CORT returned +32.42% over the past 12 months, compared with +11.79% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Corcept Therapeutics and Madrigal Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.